Udvalget for Humanmedicinske Lægemidler (CHMP) bemærkede, at Myocet var forbundet med en lavere risiko for hjerteproblemer end traditionel doxorubicin, mens begge lægemidler virkede lige effektivt.
The Committee for Medicinal Products for Human Use (CHMP) noted that Myocet has a lower risk of heart problems than conventional doxorubicin, while both medicines have similar levels of effectiveness.